Ciprofloxacin 0.3% / Dexamethasone 0.1% ear drops

ObjectiveMultiple medical therapies exist to improve outcomes following surgical management of laryngotracheal stenosis. One method involves ciprofloxacin-dexamethasone (CPD) administration into the airway, although minimal information exists on this treatment. This scoping review evaluates the current literature to understand the potential utility of CPD after airway surgery.Data sourcesPubMed, EMBASE, Cochrane Library, Scopus, Web of Science.Review methodsDatabases were searched according to PRISMA guidelines. Studies were excluded if they did not administer CPD in the airway, were solely in vitro or animal studies, or lacked full text availability.ResultsFrom 1340 studies identified, seven met inclusion criteria, and one was added from manual searching. All eight articles were published between 2008 and 2025. Four described nebulized CPD, one discussed intratracheal drops, and three evaluated both. Four studies carefully evaluated CPD to assess efficacy and side effects across an aggregate of 167 pediatric and 53 adult patients. One group demonstrated fewer postoperative bronchoscopies and a shorter hospital stay after pediatric open airway surgery. Another study showed fewer granulation tissue events and earlier decannulation for pediatric tracheostomy patients. Side effects were infrequent, and three of the four groups reported no adverse events. In the fourth study, 4.5% of surveyed pediatric otolaryngologists observed a side effect from CPD.ConclusionAlthough there is a paucity of literature regarding the safety and efficacy of CPD use in the airway, the available data suggest low risks and potential benefits. Further research is needed to assess safety, optimal treatment regimens, and efficacy of this off-label therapy.

Abstract licence: CC BY-NC 4.0

BACKGROUND: Gordonia bronchialis (G. bronchialis) is an emerging opportunistic pathogen that primarily affects immunocompromised individuals and is often associated with indwelling catheters. CASE PRESENTATION: This paper presents a case of central line-associated bloodstream infection caused by G. bronchialis in a 15-year-old male with acute myeloid leukemia (AML), highlighting diagnostic challenges and successful treatment with antimicrobial therapy. The isolate was identified as G. bronchialis using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Subsequent antimicrobial susceptibility testing revealed it to be susceptible to amikacin, amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, linezolid, minocycline, moxifloxacin, trimethoprim-sulfamethoxazole, tobramycin, cefepime, cefotaxime and doxycycline. A comprehensive literature review of 41 reported cases underscores the diverse clinical manifestations of G. bronchialis infections, including bacteremia, sternal wound infections, and osteomyelitis, with a 95.1% cure rate. Diagnostic limitations and the need for advanced microbiological techniques are discussed, emphasizing the importance of clinical awareness in immunocompromised patients. CONCLUSIONS: This review advocates for standardized treatment guidelines and further research into virulence mechanisms and biofilm-disrupting agents to combat this pathogen effectively.

Abstract licence: CC BY